Biopharmaceutical firm ImaRx has purchased the thrombolytic drug Abbokinase, the trade name for urokinase.
The acquisition complements ImaRx's existing development programs, which include recombinant urokinase and recombinant pro-urokinase, said president and CEO Dr. Evan Unger. Abbokinase, which has been commercialized for more than 20 years, is approved for the lysis of acute massive pulmonary embolism.
By AuntMinnie.com staff writers
May 9, 2006
Related Reading
ImaRx adds VP, September 8, 2005
ImaRx receives $1.1 million grant, August 2, 2005
ImaRx's SonoLysis begins phase I/II PAOD trial, April 12, 2005
ImaRx initiates SonoLysis phase II stroke trial, April 5, 2005
ImaRx raises $7 million, March 10, 2005
Copyright © 2006 AuntMinnie.com